Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

ACUTE MYELOID LEUKEMIA

Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given

Leukemia volume 39, pages 1053–1055 (2025)Cite this article

Subjects

The truth will set you free but first it will make you miserable.

President James A. Garfield

The truth will set you free but first it will make you miserable.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Weigert N, Rowe JM, Lazarus HM, Salman MY. Consolidation in AML: abundant opinion and much unknown. Blood Rev. 2022;51:100873.

    Article  PubMed  Google Scholar 

  2. Cahn JY, Labopin M, Sierra J, Blaise D, Reiffers J, Ferrant A, et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Br J Haematol. 2000;110:308–14.

    Article  CAS  PubMed  Google Scholar 

  3. Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Weisdorf D, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood. 2000;96:1254–8.

    CAS  PubMed  Google Scholar 

  4. Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM, et al. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014;20:202–8.

    Article  PubMed  Google Scholar 

  5. Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, et al. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014;120:855–63.

    Article  PubMed  Google Scholar 

  6. Rashidi A, Linden MA, DeFor TE, Warlick E, Bejanyan N, Yohe S, et al. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol. 2017;92:1032–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. How J, Vij KR, Ebadi M, DeFor TE, Romee R, Dolan MM, et al. Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol. 2018;93:E381–3.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Yeshurun M, Wolach O. When should patients receive consolidation chemotherapy before allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission? Curr Opin Hematol. 2018;25:75–80.

    Article  PubMed  Google Scholar 

  9. Zhu Y, Gao Q, Du J, Hu J, Liu X, Zhang F. Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis. Ann Hematol. 2018;97:1519–26.

    Article  CAS  PubMed  Google Scholar 

  10. Liu J, Wu D, Liu Q, Chang Y, Xu Y, Huang F, et al. More than two courses of pre-transplant consolidation therapy benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study. Chin Med J. 2023;136:1855–63.

    CAS  PubMed  Google Scholar 

  11. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482–90.

    Article  CAS  PubMed  Google Scholar 

  12. Venditti A, Gale RP, Buccisano F, Ossenkoppele G. Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant? Leukemia. 2020;34:963–5.

    Article  PubMed  Google Scholar 

  13. Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139:1694–706.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Rodríguez-Arbolí E, Othus M, Orvain C, Zarling LC, Sandmaier BM, Milano F, et al. Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Haematologica. 2023;108:273–7.

    Article  PubMed  Google Scholar 

  15. Orvain C, Rodríguez-Arbolí E, Othus M, Sandmaier BM, Deeg HJ, Appelbaum FR, et al. Association between prior cytotoxic therapy, antecedent hematologic disorder, and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Cancers. 2023;15:352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rodríguez-Arbolí E, Othus M, Freeman SD, Buccisano F, Ngai LL. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML). Leukemia. 2024;38:2266–9.

    Article  PubMed  Google Scholar 

  17. Gaut D, Oliai C, Boiarsky J, Zhang S. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2023;65:69–77.

    Article  Google Scholar 

  18. Cao Y, Huo W, Huang J, Yang Y, Wang Y, Chang Y, et al. MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study. Blood Cancer J. 2024;14:8.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zheng C, Dai R, Gale RP, Zhang MJ. Causal inference in randomized clinical trials. Bone Marrow Transplant. 2020;55:4–8.

    Article  PubMed  Google Scholar 

  21. Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55:843–50.

    Article  PubMed  Google Scholar 

  22. Gale RP, Phillips GL, Lazarus HM. A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy. Leukemia. 2024;38:1663–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Schroeder T, Wegener N, Lauseker M, Rautenberg C, Nachtkamp K, Schuler E, et al. Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transplant. 2019;25:1550–9.

    Article  PubMed  Google Scholar 

  24. El Chaer F, Perissinotti AJ, Loghavi S, Zeidan AM. Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time? Leukemia. 2024;39:1–7.

    Article  PubMed  Google Scholar 

  25. Venditti A, Piciocchi A, Candoni A, Melillo L, Cala V, Cairoli R, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134:935–45.

    Article  CAS  PubMed  Google Scholar 

  26. Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143:1931–6.

    Article  CAS  PubMed  Google Scholar 

  27. Prasad V, Gale RP. Precision medicine in acute myeloid leukemia: Hope, hype or both? Leuk Res. 2016;48:73–7.

    Article  PubMed  Google Scholar 

  28. Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, et al. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020;61:631–40.

    Article  CAS  PubMed  Google Scholar 

  29. Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12:170.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Appelbaum FR. Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Best Pract Res Clin Haematol. 2016;29:365–71.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

ER-A. is supported by a Juan Rodés fellowship from the Instituto de Salud Carlos III (JR23/00067). RPG acknowledges support from the UK National Institute of Health Research (NIHR). We sincerely thank Professors Martin Tallman, Charles Schiffer, and Andrea Bacigalupo for their review and insightful comments on our manuscript.

Author information

Authors and Affiliations

  1. Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS/CSIC), University of Seville, Seville, Spain

    E. Rodríguez-Arbolí

  2. Comprehensive Cancer Center, Atrium Health Wake Forest Baptist, Winston-Salem, NC, USA

    G. L. Phillips & T. S. Pardee

  3. Department of Medicine, Case Western Reserve University, Cleveland, OH, USA

    H. M. Lazarus

  4. Centre for Haematology, Imperial College of Science, Technology and Medicine, London, UK

    R. P. Gale

Authors
  1. E. Rodríguez-Arbolí
    View author publications

    Search author on:PubMed Google Scholar

  2. G. L. Phillips
    View author publications

    Search author on:PubMed Google Scholar

  3. T. S. Pardee
    View author publications

    Search author on:PubMed Google Scholar

  4. H. M. Lazarus
    View author publications

    Search author on:PubMed Google Scholar

  5. R. P. Gale
    View author publications

    Search author on:PubMed Google Scholar

Contributions

ER-A, GLP, HML, TSP, and RPG reviewed the data and developed the typescript. All the authours take responsibility for the content and agreed to submit it for publication.

Corresponding author

Correspondence to E. Rodríguez-Arbolí.

Ethics declarations

Competing interests

ER-A was a consultant to Astellas, Laboratoires Delbert, Kura Oncology and Servier, and received travel grants and/or speaker fees from Jazz, Astellas, AbbVie, Gilead and Eurocept. HML is a promotional speaker for Geron; Pfizer; Jazz Pharmaceuticals; and Seattle Genetics; a consultant to Actinium Pharmaceuticals, Inc; Pluristem Therapeutics Inc; CSL Behring; GlycoMimetics; a consultant with stock options for Partner Therapeutics; and member of the Data Safety Monitoring Board for Bristol-Myers Squibb; and BioSight. RPG is a consultant to Antengene Biotech LLC; Consultant Shenzen TargetRx; Medical Director, FFF Enterprises Inc; A speaker for Janssen Pharma, BeiGene and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support and Scientific Advisory Board, StemRad Ltd. TSP has been an Advisory Board Member for AbbVie, Genentech, and Karyopharm; research support from Karyopharm and Delta Fly Pharmaceuticals.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rodríguez-Arbolí, E., Phillips, G.L., Pardee, T.S. et al. Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given. Leukemia 39, 1053–1055 (2025). https://doi.org/10.1038/s41375-025-02560-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41375-025-02560-3

This article is cited by

Search

Advanced search

Quick links